Gilead (GILD) stock slips as Yeztugo outlook keeps traders on edge
Gilead Sciences shares fell 1.8% to $152.94 Thursday, giving back gains after its 2026 outlook and Yeztugo sales forecast missed some analyst expectations. The company projected $800 million in 2026 Yeztugo sales, below consensus. Fourth-quarter revenue rose 5% to $7.9 billion. Several brokerages raised price targets despite policy and pricing concerns.